ONS/ONCC Chemotherapy Immunotherapy Certification Actual Exam 2026/2027 with
Detailed Rationales | Complete Exam-Style Questions | Pass Guaranteed – A+ Graded
EXAM INFORMATION
Total Questions: 60
Recommended Time: 90 minutes
Passing Threshold: 85%
Exam Format: Multiple Choice Questions (MCQs)
Question Style: Scenario-Based, Applied, and Professional Decision-Making Questions
==============================
SECTION 1: Pharmacology and Mechanism of Action
Question 1: A patient with HER2-positive breast cancer is receiving trastuzumab. The
nurse understands that this monoclonal antibody exerts its antitumor effect primarily
through which mechanism?
A. Inhibition of tyrosine kinase signaling in the epidermal growth factor receptor
pathway
B. Binding to the extracellular domain of HER2, leading to receptor internalization and
antibody-dependent cellular cytotoxicity
C. Cross-linking of DNA strands to prevent replication and transcription
D. Inhibition of microtubule polymerization, causing metaphase arrest
Correct Answer: B
,Rationale: Trastuzumab is a humanized monoclonal antibody that binds to the
extracellular juxtamembrane domain of the HER2 receptor. This binding results in
receptor internalization, inhibition of HER2-mediated signaling, and induction of
antibody-dependent cellular cytotoxicity (ADCC). Option A describes the mechanism of
tyrosine kinase inhibitors such as lapatinib. Option C describes the mechanism of
alkylating agents such as cyclophosphamide. Option D describes the mechanism of
taxanes such as paclitaxel.
Question 2: A patient with B-cell acute lymphoblastic leukemia is prescribed
blinatumomab. The nurse recognizes that this agent is classified as which type of
immunotherapy?
A. Chimeric antigen receptor T-cell therapy
B. Bispecific T-cell engager
C. Immune checkpoint inhibitor
D. Monoclonal antibody targeting CD20
Correct Answer: B
Rationale: Blinatumomab is a bispecific T-cell engager (BiTE) that simultaneously binds
CD19 on B-cell malignancies and CD3 on T cells, directing cytotoxic T-cell activity
against CD19-expressing tumor cells. Option A refers to CAR-T therapies such as
tisagenlecleucel. Option C refers to agents such as pembrolizumab or nivolumab.
Option D refers to agents such as rituximab or obinutuzumab.
,Question 3: A patient receiving oxaliplatin for colorectal cancer develops acute
neurotoxicity characterized by paresthesias triggered by cold exposure. The nurse
understands that this adverse effect is most likely caused by which mechanism?
A. Direct damage to Schwann cells leading to demyelination
B. Inhibition of voltage-gated sodium channels in peripheral nerves
C. Oxidative stress and mitochondrial dysfunction in dorsal root ganglia neurons
D. Cross-linking of DNA in neuronal cell bodies
Correct Answer: C
Rationale: Oxaliplatin-induced neurotoxicity is primarily attributed to oxidative stress
and mitochondrial dysfunction in dorsal root ganglia neurons, leading to axonal
degeneration. The acute form, characterized by cold-induced paresthesias and
pharyngolaryngeal dysesthesia, is thought to involve transient dysfunction of
voltage-gated sodium channels, but the underlying mechanism involves accumulation
of oxaliplatin metabolites and oxidative damage. Chronic cumulative neurotoxicity
results from persistent mitochondrial and axonal damage.
Question 4: A patient with metastatic melanoma is receiving ipilimumab. The nurse
understands that this agent enhances antitumor immunity by which mechanism?
A. Blocking programmed death-1 (PD-1) receptor on T cells
B. Blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to enhance T-cell
activation
C. Inhibiting vascular endothelial growth factor (VEGF) to reduce tumor angiogenesis
D. Activating natural killer cells through interleukin-2 signaling
, Correct Answer: B
Rationale: Ipilimumab is a fully human monoclonal antibody that blocks CTLA-4, a
negative regulator of T-cell activation expressed on activated T cells and regulatory T
cells. By blocking CTLA-4, ipilimumab enhances T-cell activation and proliferation,
leading to increased antitumor immune responses. Option A describes the mechanism
of anti-PD-1 agents such as nivolumab or pembrolizumab. Option C describes the
mechanism of bevacizumab. Option D describes the mechanism of high-dose
interleukin-2 therapy.
Question 5: A patient with hormone receptor-positive breast cancer is receiving
palbociclib in combination with letrozole. The nurse understands that palbociclib exerts
its antitumor effect by which mechanism?
A. Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), preventing cell cycle
progression from G1 to S phase
B. Competitive inhibition of estrogen receptor binding to DNA
C. Inhibition of aromatase, reducing peripheral estrogen synthesis
D. Inhibition of mammalian target of rapamycin (mTOR) signaling
Correct Answer: A
Rationale: Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6
(CDK4/6), which are critical regulators of cell cycle progression from G1 to S phase. By
inhibiting CDK4/6, palbociclib prevents phosphorylation of the retinoblastoma protein,
leading to cell cycle arrest. Option B describes the mechanism of tamoxifen. Option C
describes the mechanism of letrozole or other aromatase inhibitors. Option D describes
the mechanism of everolimus.
Detailed Rationales | Complete Exam-Style Questions | Pass Guaranteed – A+ Graded
EXAM INFORMATION
Total Questions: 60
Recommended Time: 90 minutes
Passing Threshold: 85%
Exam Format: Multiple Choice Questions (MCQs)
Question Style: Scenario-Based, Applied, and Professional Decision-Making Questions
==============================
SECTION 1: Pharmacology and Mechanism of Action
Question 1: A patient with HER2-positive breast cancer is receiving trastuzumab. The
nurse understands that this monoclonal antibody exerts its antitumor effect primarily
through which mechanism?
A. Inhibition of tyrosine kinase signaling in the epidermal growth factor receptor
pathway
B. Binding to the extracellular domain of HER2, leading to receptor internalization and
antibody-dependent cellular cytotoxicity
C. Cross-linking of DNA strands to prevent replication and transcription
D. Inhibition of microtubule polymerization, causing metaphase arrest
Correct Answer: B
,Rationale: Trastuzumab is a humanized monoclonal antibody that binds to the
extracellular juxtamembrane domain of the HER2 receptor. This binding results in
receptor internalization, inhibition of HER2-mediated signaling, and induction of
antibody-dependent cellular cytotoxicity (ADCC). Option A describes the mechanism of
tyrosine kinase inhibitors such as lapatinib. Option C describes the mechanism of
alkylating agents such as cyclophosphamide. Option D describes the mechanism of
taxanes such as paclitaxel.
Question 2: A patient with B-cell acute lymphoblastic leukemia is prescribed
blinatumomab. The nurse recognizes that this agent is classified as which type of
immunotherapy?
A. Chimeric antigen receptor T-cell therapy
B. Bispecific T-cell engager
C. Immune checkpoint inhibitor
D. Monoclonal antibody targeting CD20
Correct Answer: B
Rationale: Blinatumomab is a bispecific T-cell engager (BiTE) that simultaneously binds
CD19 on B-cell malignancies and CD3 on T cells, directing cytotoxic T-cell activity
against CD19-expressing tumor cells. Option A refers to CAR-T therapies such as
tisagenlecleucel. Option C refers to agents such as pembrolizumab or nivolumab.
Option D refers to agents such as rituximab or obinutuzumab.
,Question 3: A patient receiving oxaliplatin for colorectal cancer develops acute
neurotoxicity characterized by paresthesias triggered by cold exposure. The nurse
understands that this adverse effect is most likely caused by which mechanism?
A. Direct damage to Schwann cells leading to demyelination
B. Inhibition of voltage-gated sodium channels in peripheral nerves
C. Oxidative stress and mitochondrial dysfunction in dorsal root ganglia neurons
D. Cross-linking of DNA in neuronal cell bodies
Correct Answer: C
Rationale: Oxaliplatin-induced neurotoxicity is primarily attributed to oxidative stress
and mitochondrial dysfunction in dorsal root ganglia neurons, leading to axonal
degeneration. The acute form, characterized by cold-induced paresthesias and
pharyngolaryngeal dysesthesia, is thought to involve transient dysfunction of
voltage-gated sodium channels, but the underlying mechanism involves accumulation
of oxaliplatin metabolites and oxidative damage. Chronic cumulative neurotoxicity
results from persistent mitochondrial and axonal damage.
Question 4: A patient with metastatic melanoma is receiving ipilimumab. The nurse
understands that this agent enhances antitumor immunity by which mechanism?
A. Blocking programmed death-1 (PD-1) receptor on T cells
B. Blocking cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to enhance T-cell
activation
C. Inhibiting vascular endothelial growth factor (VEGF) to reduce tumor angiogenesis
D. Activating natural killer cells through interleukin-2 signaling
, Correct Answer: B
Rationale: Ipilimumab is a fully human monoclonal antibody that blocks CTLA-4, a
negative regulator of T-cell activation expressed on activated T cells and regulatory T
cells. By blocking CTLA-4, ipilimumab enhances T-cell activation and proliferation,
leading to increased antitumor immune responses. Option A describes the mechanism
of anti-PD-1 agents such as nivolumab or pembrolizumab. Option C describes the
mechanism of bevacizumab. Option D describes the mechanism of high-dose
interleukin-2 therapy.
Question 5: A patient with hormone receptor-positive breast cancer is receiving
palbociclib in combination with letrozole. The nurse understands that palbociclib exerts
its antitumor effect by which mechanism?
A. Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), preventing cell cycle
progression from G1 to S phase
B. Competitive inhibition of estrogen receptor binding to DNA
C. Inhibition of aromatase, reducing peripheral estrogen synthesis
D. Inhibition of mammalian target of rapamycin (mTOR) signaling
Correct Answer: A
Rationale: Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6
(CDK4/6), which are critical regulators of cell cycle progression from G1 to S phase. By
inhibiting CDK4/6, palbociclib prevents phosphorylation of the retinoblastoma protein,
leading to cell cycle arrest. Option B describes the mechanism of tamoxifen. Option C
describes the mechanism of letrozole or other aromatase inhibitors. Option D describes
the mechanism of everolimus.
